Stock Market Reviews

Read and share opinions on NVS (Novartis AG) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Novartis Selects ​Salesforce’s (CRM) Agentforce Life Sciences for Customer Engagement
  Dec 28, 2025
• Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally
  Dec 17, 2025
• HSBC Lifts PT on Novartis AG (NVS) to $112 From $106
  Dec 16, 2025

NVS News

• Novartis Selects ​Salesforce’s (CRM) Agentforce Life Sciences for Customer Engagement
  ​Salesforce, Inc. (NYSE:CRM) is one of the Best Quality Stocks to Buy Before 2026. On December 17, Salesforce, Inc. (NYSE:CRM) announced that Novartis (NYSE:NVS) has selected the company’s Agentforce Life Sciences for Customer Engagement to connect patients and Healthcare professional experiences. ​Novartis has already invested in the company through Agentforce Health, 360 for Health & […]
  Dec 28, 2025
• How Investors May Respond To Salesforce (CRM) Q3 Beat And Surging Enterprise AI Adoption
  In recent weeks, Salesforce reported record third-quarter fiscal 2026 results, raised its full-year guidance, and highlighted rapid adoption of its AI products Agentforce and Data 360, underpinned by new deployments at organizations such as Novartis, the U.S. Department of Transportation, and DeVry University. These developments point to Salesforce’s AI platform becoming more deeply embedded in critical workflows across healthcare, government, and education, potentially reinforcing customer...
  Dec 24, 2025
• Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill
  On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.
  Dec 23, 2025
• Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
  Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
  Dec 22, 2025
• 2 Top Stocks to Buy and Hold for the Long Term
  Both have crushed the market this year.
  Dec 22, 2025
• Radiopharmaceutical specialist Aktis seeks an IPO
  The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.
  Dec 22, 2025
• Trump reaches deal with 9 drug companies to lower prices
  President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
  Dec 19, 2025
• IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries
  Among the most significant projects is Novartis' decision to build a new production facility for radioligand therapies in Halle (Saale). The technology is considered groundbreaking in personalized cancer medicine. With this new site, the state not only strengthens its life sciences sector but also gains additional international visibility. Saxony-Anhalt's Minister for Economic Affairs, Sven Schulze, emphasizes: "This investment shows the great confidence in our state's innovative strength and re
  Dec 19, 2025
• Pharma's $370B Bet on America: The ETF Plays for 2026
  Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
  Dec 19, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t
  Dec 19, 2025
• Nine Drugmakers Strike Deals With Trump, With More to Come
  The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.
  Dec 19, 2025
• Novartis and US government reach agreement on lowering drug prices in the US
  Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to low
  Dec 19, 2025
• Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
  Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
  Dec 19, 2025
• More Drugmakers Reach Deals With White House to Lower Prices
  The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
  Dec 19, 2025
• EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
  INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
  Dec 18, 2025
• Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials
  Viatris (VTRS) said Thursday the US Food and Drug Administration approved octreotide acetate for inj
  Dec 18, 2025
• Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally
  SAN FRANCISCO, December 17, 2025--Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative medicines company, has selected Salesforce’s Agentforce Life Sciences for Customer Engagement to connect patient and healthcare professional (HCP) experiences, enabling teams to focus on strategic and meaningful customer interactions. Building upon its existing investments with Agentforce Health, Data 360 for Health & Life Sciences, MuleSoft for
  Dec 17, 2025
• HSBC Lifts PT on Novartis AG (NVS) to $112 From $106
  Novartis AG (NYSE:NVS) is one of the most profitable NYSE stocks to buy right now. HSBC lifted the price target on Novartis AG (NYSE:NVS) to $112 from $106 on December 10 while maintaining a Reduce rating on the shares. The rating update came as part of the 2026 outlook for the pharma group, with the firm […]
  Dec 16, 2025
• Top Research Reports for Microsoft, Novartis & RTX
  Microsoft, Novartis and RTX headline Zacks' top research picks, spotlighting cloud, pharma innovation and defense demand shaping market leaders.
  Dec 15, 2025
• Has Novartis’ 24.5% Surge Left Further Upside After Strong Pipeline and Cash Flow Gains?
  Many investors may be wondering whether Novartis is still worth considering after its big run, or if most of the potential upside is already reflected in the share price. The stock is up 18.5% year to date and 24.5% over the last year, with the share price around $105.50 even after a modest 1.5% pullback over the past week. Those gains have been supported by a steady stream of pipeline updates, regulatory approvals and portfolio reshaping moves that have reinforced Novartis' position as a...
  Dec 14, 2025
• Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report
  We recently published 13 Best ADR Stocks to Invest In. Novartis AG (NYSE:NVS) is one of the best ADR stocks. Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion partnership with British pharmaceutical firm Relation Therapeutics to develop treatments for allergic diseases, according to a report from Bloomberg which surfaced on […]
  Dec 12, 2025
• Novartis breaks ground on flagship manufacturing hub in North Carolina
  Figure 1 Novartis executives, federal, state and local officials gather for a groundbreaking at the company's flagship manufacturing hub in Durham, North Carolina, Thursday, December 11, 2025 Figure 2 Novartis CEO Vasant (Vas) Narasimhan, MD, pictured with North Carolina Governor Josh Stein at the company's flagship manufacturing hub groundbreaking in Durham, NC, Thursday, December 11, 2025 FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight import
  Dec 12, 2025
• Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001
  Sen-Jam Pharmaceutical, a clinical-stage biotechnology company pioneering novel anti-inflammatory combination therapeutics, today announced a transformative partnership with TASK Clinical, a global contract research organization (CRO). Under the agreement, TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity — an exceptionally rare commitment that significantly de-risks development, enhances investor confidence, and strengthens the program
  Dec 11, 2025
• Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035
  The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is risin
  Dec 11, 2025
• Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
  This discovery deal falls under Novartis’ wider ploy to strengthen its immunology portfolio.
  Dec 11, 2025
• Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan
  Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in. On December 8, Novartis AG (NYSE:NVS) was upgraded to Overweight from Neutral by JPMorgan. The firm lifted the price target to CHF 125 from CHF 95, releasing adjusted ratings for companies under its coverage in the European pharma group as part of its […]
  Dec 10, 2025
• Novartis (SWX:NOVN) Valuation After Key Ianalumab Phase III Success and Expanded Itvisma FDA Approval
  Novartis (SWX:NOVN) is back on many investors radar after two clear clinical wins: a broader US FDA approval for Itvisma in spinal muscular atrophy and strong Phase III data for ianalumab in immune thrombocytopenia. See our latest analysis for Novartis. These clinical and AI discovery wins are landing against a supportive backdrop, with Novartis’ share price up about 20% year to date and a 1 year total shareholder return near 25%, signalling solid, sustained momentum rather than a short term...
  Dec 10, 2025
• How Novartis’ AI-Enabled Atopic Disease Alliance with Relation Therapeutics Will Impact Novartis (SWX:NOVN) Investors
  On 9 December 2025, Relation Therapeutics announced a multi-program collaboration with Novartis, securing US$55 million in upfront, equity and R&D funding, plus eligibility for up to US$1.70 billion in milestones and tiered royalties to discover AI-enabled drug targets for atopic diseases. The alliance pairs Relation’s AI and human tissue data platform with Novartis’s immuno-dermatology expertise, aiming to validate first-in-class targets more effectively by grounding discovery directly in...
  Dec 10, 2025
• Tristan Imbert co-opted as Independent Director
  Press Release Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to the vote of EUROAPI Shareholders’ meeting on May 27, 2026. Tristan Imbert will be appointed Chair of the Audit Committee, effective Janua
  Dec 10, 2025
• Novartis Drops $1.7 Billion on AI Allergy Breakthrough
  A quiet JPMorgan hallway chat just birthed one of 2025's most ambitious biotech plays. Here's why it could matter.
  Dec 9, 2025
• 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
  Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positi
  Dec 9, 2025
• Novartis AG (NVS) Announces US FDA Approval of Itvisma®
  Novartis AG (NYSE:NVS) is one of the Most Undervalued Stocks to Buy Right Now. On November 24, the company announced that the US FDA approved Itvisma® (onasemnogene abeparvovec-brve) for treating children of 2 years and older, teens, and adults having spinal muscular atrophy (SMA) with a confirmed mutation in the survival motor neuron 1 (SMN1) gene. Novartis AG (NYSE:NVS) […]
  Dec 9, 2025
• Sen-Jam Pharmaceutical Appoints Global Life Sciences Leader Rute Fernandes as Executive Advisor to Accelerate Commercialization Pathways
  Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics for inflammation-driven conditions, today announced the appointment of Rute Fernandes as Executive Advisor to support commercialization strategy, scenario planning, and launch readiness across the company's advancing pipeline.
  Dec 9, 2025
• Cancer Study Buoys These Small Biotechs
  Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm’s once-daily pill.
  Dec 9, 2025
• Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
  Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with ianalumab plus eltrombopag achieved sustained platelet response at six months compared to 39% with placebo plus eltrombopag1,2Ianalumab, administered as four once-monthly intravenous doses in the ITP setting, has the potential to reduce the need for chronic treatment and deliver durable disease contr
  Dec 9, 2025
• Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
  LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive $55 million, comprising an upfront payment, equity investment and additional R&D funding. In addition, Relation is eligible to receive preclinical, development, regulatory, and commercial sales milestones of up to $1.7 billion, along with tiered royalties on net
  Dec 9, 2025
• Novartis notches another win for drug acquired in MorphoSys deal
  Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low platelet counts.
  Dec 9, 2025
• Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.
  Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.
  Dec 8, 2025
• Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035
  Neuroblastoma, a rare cancer mainly affecting children, is witnessing advancements in treatments, notably through immunotherapy, which has improved survival rates. Key innovations like gene and CAR-T cell therapies are accelerated by substantial government and private investments, transforming market dynamics. However, high treatment costs pose a challenge, particularly in low-resource settings. Leaders like Novartis and Eli Lilly drive innovation, focusing on sustainable products. The market's
  Dec 8, 2025
• DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks
  During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 111 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up
  Dec 8, 2025
• Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test?
  In early December 2025, Janux Therapeutics reported updated interim Phase 1 data for JANX007 in metastatic castration-resistant prostate cancer, showing anti-tumor activity with partial responses in 30% of evaluable patients and radiographic progression-free survival of 7.9 to 8.9 months. Despite Janux characterizing the results as positive, investors questioned whether JANX007 can compete with established options such as Novartis’s Pluvicto, putting the company’s broader TRACTr platform...
  Dec 6, 2025
• Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
  Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
  Dec 5, 2025
• Avidity Biosciences, Inc. (RNA): A Bull Case Theory
  We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.’s share was trading at $71.54 as of December 2nd. Novartis is acquiring Avidity RNA, a pre-Phase 3 biotech company, in a straightforward deal with no overlap between the two businesses. The […]
  Dec 4, 2025
• How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter
  Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus.
  Dec 4, 2025
• Sector Update: Health Care Stocks Higher Late Afternoon
  Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He
  Dec 3, 2025
• Intraocular Lens Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue
  The intraocular lens (IOL) market is projected to grow from US$ 4.46 billion in 2024 to US$ 7.16 billion by 2033, reflecting a CAGR of 5.41%. This booming industry is driven by the rising prevalence of cataracts and an aging population, alongside technological advancements in lens solutions such as multifocal and toric lenses. Major players like Novartis, Johnson & Johnson, and Alcon are spearheading innovations to enhance visual outcomes and meet global market demands, particularly in emerging
  Dec 3, 2025
• ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman
  By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth and leadership in rare and inflammatory diseases,” said Kenji Cunnion, M.D., MPH, ReAlta’s co-founder, Chief […]
  Dec 2, 2025
• Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
  BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501, and related assets (together “TZLS-501”) via a spinout into a separate publicly traded company, to enhance the strategic focus of each company and to drive value for shareholders. Tiziana shar
  Dec 2, 2025
• Nanopharmaceuticals Research Report 2025: Market to Reach $104.58 Billion by 2030, Driven by Rising Chronic Disease Burden and Growing Investment in Regenerative Medicine and Nanotechnology Drugs
  The nanopharmaceuticals market presents opportunities in addressing chronic diseases through enhanced targeted therapies and bioavailability. Personalization in treatments, particularly in oncology, is a key trend. However, high R&D costs and regulatory hurdles pose challenges. Key players include Merck, Pfizer, and Novartis. Nanopharmaceuticals Market Nanopharmaceuticals Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Oppor
  Dec 2, 2025
• Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%.
  Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.
  Dec 2, 2025
• ARWR: Multiple Data Readouts Ahead in 2026…
  By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Data Readouts Ahead in 2026 Following the recent approval of REDEMPLO ® for the treatment of patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week
  Dec 1, 2025
• Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
  The colorectal cancer market is growing due to rising incidence driven by aging populations and lifestyle risk factors, which increases demand for screening and treatment. Advances in molecular diagnostics, targeted therapies, and immuno-oncology agents are expanding treatment options and prolonging patient survival. Additionally, the launch of emerging therapies such as Serplulimab (HLX10) + Bevacizumab + Chemotherapy (Shanghai Henlius Biotech), Botensilimab ± Balstilimab (Agenus), TTX-080 (Tiz
  Dec 1, 2025
• Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer
  MUTTENZ, Switzerland, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company pioneering innovation in peritoneal dialysis (PD), is pleased to announce the appointment of Andreas Schuh as Chief Financial Officer (CFO), effective December 1, 2025. Andreas Schuh joins Opterion with over 20 years of leadership experience across biotech, pharma, and medical devices. He has held senior finance and operations roles at Nuclidium, Jeito, Roivant, Novartis, and Al
  Dec 1, 2025
• U.S., U.K. Strike Deal on Higher Drug Prices
  The move marks a victory for the Trump administration’s campaign to get other countries to pay more for drugs.
  Dec 1, 2025
• TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029
  Novartis AG (NYSE:NVS) ranks among the best slow growth stocks to invest in. Following meetings with Novartis AG (NYSE:NVS)’s head of U.S. operations in Boston, New York, and San Francisco, TD Cowen reaffirmed its Hold rating on the company’s shares on November 10 with a price target of $140. The meetings revealed a number of […]
  Nov 29, 2025
• Are Novartis Shares Attractive After 17.5% Rise and Pipeline Progress in 2025?
  If you have ever wondered whether Novartis shares are worth their current price, you are not alone. Many investors are trying to pinpoint whether there is real value up for grabs. Shares have moved up a solid 5.8% in the last month and are up an impressive 17.5% year-to-date, hinting at shifting sentiment and growth potential. Rumors of strategic partnerships and ongoing success in the company’s drug pipeline have sparked renewed interest, while regulatory updates have also helped fuel the...
  Nov 28, 2025
• Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches
  Market growth is propelled by improved diagnosis, genetic screening, and emerging therapies like statins, PCSK9 inhibitors, and gene therapies. Challenges include underdiagnosis and delayed treatment. Key players like Regeneron and Amgen are pioneering innovative solutions, enhancing the market landscape with precision medicine and genetic advancements.Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Familial Hypercholesterolemia Market - A Global and Regional Analysis: Focus on Country and Region
  Nov 27, 2025
• Here's Why Novus Holdings (JSE:NVS) Has Caught The Eye Of Investors
  It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
  Nov 26, 2025
• Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ...
  Arrowhead Pharmaceuticals Inc (ARWR) achieves a milestone with FDA approval of Redemplo and secures a lucrative partnership with Novartis, despite facing financial and developmental challenges.
  Nov 26, 2025
• Why Novartis Stock Topped the Market Today
  The company has a brand-new product to ship to pharmacies.
  Nov 26, 2025
• Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
  The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.
  Nov 26, 2025
• Novartis axes 550 jobs at Swiss manufacturing site
  The Swiss pharma’s Stein site will discontinue solid dose manufacturing in favour of sterile dose production.
  Nov 26, 2025
• Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025
  Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari.
  Nov 26, 2025
• Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
  Health care stocks were edging higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) up
  Nov 25, 2025
• 4 takeaways from pharma’s manufacturing boom
  As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.
  Nov 25, 2025
• BofA upgrades Novartis and GSK as pivotal data, new launches approach
  Investing.com -- Bank of America (BofA) has turned more constructive on two of Europe’s largest drugmakers, upgrading Novartis to Buy and GSK to Neutral as both companies approach a heavy year of product launches and pivotal readouts that could define their mid-term growth paths.
  Nov 25, 2025
• Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Tuesday Ahead of Delayed Data Releases
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad
  Nov 25, 2025
• Workday Announces Fiscal 2026 Third Quarter Financial Results
  Workday, Inc. (NASDAQ: WDAY), the enterprise AI platform for managing people, money, and agents, today announced results for the fiscal 2026 third quarter ended October 31, 2025.
  Nov 25, 2025
• Novartis Canada Welcomes Dimitri Gitas as New Country President
  Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the appointment of Dimitri Gitas as Country President, effective December 1, 2025. As a proud Canadian returning home, Dimitri brings more than 20 years of experience in life sciences and healthcare, with a proven track record of leadership in Canada, the United States, Greece, Poland and Switzerland where he most recently served as Managing Director for MSD.
  Nov 25, 2025
• Novartis (SWX:NOVN): Evaluating Valuation as Shares Outperform with 17% Year-to-Date Return
  Novartis (SWX:NOVN) shares have recently attracted attention as investors revisit the company’s solid track record and steady performance in the pharmaceuticals sector. With modest returns over the past quarter, market watchers are considering its current valuation. See our latest analysis for Novartis. Novartis has seen its share price strengthen notably this year, with a year-to-date share price return of 17.48%, which points to renewed investor optimism. The company’s one-year total...
  Nov 25, 2025
• Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community
  The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA). Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community The Muscular Dystrophy Association calls FDA approval of Novartis’ Itvisma (onasemnogene abeparvovec-brve) a major step forward for the spinal muscular atrophy community. New York, Nov. 24, 2025 (GLOBE NEWSWIRE)
  Nov 25, 2025
• FDA Greenlights Novartis' Gene Replacement Treatment for SMA
  Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
  Nov 25, 2025
• Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
  PASADENA, Calif., November 25, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results.
  Nov 25, 2025
• Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
  Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trialKisqali NATALEE and MONALEESA data add to evidence of long-term benefits for early and metastatic breast ca
  Nov 25, 2025
• FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy
  Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.
  Nov 25, 2025
• Labcorp Appoints Victor Bulto to Board of Directors
  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.
  Nov 24, 2025
• Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
  Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studiesOne-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatmentGene replacement therapy now available to eligible people of all ages living with SMA Basel, November 24, 2025 – Novartis today announced that the US Food and Drug Administration (FDA) has appro
  Nov 24, 2025
• NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
  Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
  Nov 21, 2025
• Novartis Lifts Outlook With Stronger Peak Sales Forecasts
  Company boosts peak sales targets and maintains 40%+ margins
  Nov 21, 2025
• Novartis to build manufacturing hub in North Carolina with $771M investment
  The medicine maker is adding three new production facilities across Durham and Morrisville, and expanding a fourth facility in the area, as part of a broader $23 billion investment plan.
  Nov 21, 2025
• Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
  Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for Kisqali and Scemblix; Novartis now has eight de-risked, in-market assets with USD 3-10 billion peak sales potential15+ potentially submission-enabling readouts expected in the next two years to fuel long-term growth Pipeline includes 30+ potential high-value medicines, with 10+ licensed or acquired in
  Nov 20, 2025
• US healthcare group Abbott bets on cancer screening technology in $23bn deal
  US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...
  Nov 20, 2025
• Novartis Hikes Cancer Drug Targets--Signals Billions More in Pipeline Firepower
  Fresh guidance on Kisqali and Scemblix puts oncology back in the driver's seat as Novartis preps for 2026 trial blitz.
  Nov 20, 2025
• European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
  European equities traded in the US as American depositary receipts were modestly higher late Thursda
  Nov 20, 2025
• Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Jobs Data
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1.4% and the actively trad
  Nov 20, 2025
• Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110
  Novartis AG (NYSE:NVS) is included among the 12 Best European Dividend Stocks to Buy Now. O⁠n October 31, Morgan‍ Stanley upgraded Novartis AG (NYSE:NVS) to‍ Overw‍eight from E‌qu‌al Weight, raising its​ price​ target to CHF 110⁠ f‍rom CHF 108, as reported by The Fly. The firm cited an attractive valuation following the recent market sell-off. […]
  Nov 20, 2025
• Malaria Breakthrough Might Change The Case For Investing In Novartis (SWX:NOVN)
  Novartis recently announced positive Phase III results from its KALUMA study of GanLum (ganaplacide/lumefantrine), a new malaria treatment targeting growing drug resistance in Africa, with details presented at a major global tropical medicine meeting. This achievement, realized through international partnership and collaboration, highlights Novartis’ efforts to address urgent global health challenges through high-impact innovation in infectious diseases. We'll examine how the advancement of...
  Nov 20, 2025
• Novartis taps North Carolina as new manufacturing hub location
  The two new sites fall under the Swiss pharma’s $23bn US manufacturing onshoring strategy.
  Nov 20, 2025
• Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s
  The drugmaker is confronting investor concerns about patent expirations as it moves forward with a $23 billion plan to bolster its U.S. footprint.
  Nov 20, 2025
• Soft Tissue Sarcoma Market Analysis Report 2025-2035, Profiles of Novartis, Nanobiotix, Adaptimmune, and Ipsen Pharma
  The global soft tissue sarcoma market is poised for substantial growth from 2024 to 2035, driven by the rising prevalence of this rare, aggressive cancer affecting connective tissues. Key growth factors include advancements in targeted therapies, immunotherapies, and innovative surgical techniques. Enhanced diagnosis and treatment options, supported by personalized medicine and genetic profiling, further boost this market. North America holds a significant market share due to its advanced health
  Nov 19, 2025
• Novartis announces plans to build flagship manufacturing hub in North Carolina
  Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic areas in one geographic locationMarks latest milestone in company’s previously announced $23 billion investment in US infrastructure East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a ne
  Nov 19, 2025
• Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics
  The global inherited retinal disease market is poised for significant growth by 2025, driven by increasing prevalence of retinal conditions and advancements in genetic and cell-based therapies. Key diseases include retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease, which lead to progressive vision loss. Gene therapies and stem cell treatments are transforming the market alongside precision medicine advancements. While cost remains a barrier, emerging markets and regenerativ
  Nov 19, 2025
• Portal Hypertension Drugs Market Research Report 2025-2035: Key Dynamics, Pipeline Analysis, Regulatory Landscape, Epidemiology
  The global portal hypertension drugs market is thriving due to rising liver disease rates, particularly cirrhosis and hepatitis, and an aging global population, leading to heightened demand for effective therapies. Key players like Gilead Sciences and Novartis are driving market growth through innovation and strategic partnerships. Despite challenges such as high treatment costs and limited access, ongoing R&D aims to introduce affordable solutions. As awareness of liver health expands, technolo
  Nov 19, 2025
• Competition Bureau expands its investigation into BWX Technologies' acquisition of Kinectrics
  As part its ongoing investigation into BWX Technologies' acquisition of Kinectrics, the Competition Bureau has obtained court orders to gather information from Novartis and certain subsidiaries. Novartis, along with the merged firm, is involved in the manufacture and sale of nuclear medicine products in Canada.
  Nov 19, 2025
• Intestinal Fistula Market Analysis Report 2025-2035: Competition Intensifies as Sanofi and Novartis Drive Innovation Through Strategic Partnerships and Advanced Treatment Expansion
  The global intestinal fistula market is witnessing steady growth driven by advancements in medical treatments, increased awareness of gastrointestinal health, and rising demand for effective management of complex conditions. Innovations in biologics, nutrition therapies, and surgical techniques are reshaping the market landscape, enhancing patient outcomes. With growing healthcare spending and infrastructure in the U.S., Europe, and emerging economies, the market is set for expansion. Key player
  Nov 18, 2025
• Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
  The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio
  Nov 18, 2025
• Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
  NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
  Nov 13, 2025
• Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
  Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate of 97.4% based on estimand method, equating to 99.2% under conventional per protocol analysis If approved, GanLum would represent first major innovation in malaria treatment since 1999, with potential to kill drug-resistant parasites and block transmissionNovel ingredient in GanLum, ganaplacide, has
  Nov 12, 2025
• First New Malaria Drug in Years Performs Strongly in Late-Stage Testing
  Novartis said its experimental treatment cured more than 99% of malaria cases in the trial, marking a big step toward approval.
  Nov 12, 2025
• Sector Update: Health Care Stocks Advance Monday Afternoon
  Health care stocks rose Monday afternoon with the NYSE Health Care Index and the Health Care Select
  Nov 10, 2025
• Sector Update: Health Care Stocks Advance Late Afternoon
  Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He
  Nov 10, 2025
• Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
  Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and HawaiiFirst to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas Basel, November 10, 2025 – Novartis, a leading global innovative medicines compan
  Nov 10, 2025
• This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed.
  The founders of Metsera had a battle to buy their company. It’s their second time striking deal gold.
  Nov 8, 2025
• More Drugs to Fight High Cholesterol Are Emerging
  The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades. Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon. Certain patients already can take a twice-yearly injection, sold by Novartis as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.
  Nov 8, 2025
• Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players
  The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co
  Nov 6, 2025
• Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
  Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 inflammasome; initial readout including data from high-CVD risk cohort on track for H1 2026 VAV1-directe
  Nov 6, 2025
• Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players
  Key market opportunities for needle-free devices lie in technological advancements, regional expansion across Asia-Pacific and MEA, and growing applications in vaccines, pain management, and insulin delivery. Strategic alliances and innovations from major players like GSK and Novartis can further drive growth. Global Needle-Free Devices Market Global Needle-Free Devices Market Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Needle-Free Devices: Technologies and Global Markets" has been added to R
  Nov 6, 2025
• Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year.
  Celcuity hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534% this year.
  Nov 6, 2025
• Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034
  The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMark
  Nov 5, 2025
• New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
  Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients V-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patientsLp(a) data underscore importanc
  Nov 4, 2025
• Solid Earnings Reflect Novartis' (VTX:NOVN) Strength As A Business
  Novartis AG ( VTX:NOVN ) just reported healthy earnings but the stock price didn't move much. We think that investors...
  Nov 4, 2025
• Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger
  We recently published 10 Stocks With Easy 20-40% Gains. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the last week’s best-performing stocks. Avidity Biosciences climbed by 42.1 percent week-on-week, as investors gobbled up shares after confirming a $12 billion merger plan with Novartis AG. Earlier in the week, Novartis said it entered into an agreement with […]
  Nov 3, 2025
• United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb
  Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and
  Nov 3, 2025
• Meharry and Novartis Partner on HEART Initiative for Healthier Communities
  NASHVILLE, Tenn., November 03, 2025--The School of Global Health at Meharry Medical College, in partnership with Novartis, today announced the launch of Health Assessments and Rapid Transformation (HEART), a five-year initiative that aims to improve heart health in three US cities through population health approaches addressing clinical and non-clinical determinants of health. Guided by community voices and powered by research, policy, and technology, HEART seeks to reduce cardiovascular health
  Nov 3, 2025
• Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
  Novartis is set to boost its developmental pipeline with this acquisition.
  Oct 31, 2025
• Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
  IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
  Oct 30, 2025

NVS Reviews

• MemeInvestor

  Dec 30, 2025

  $NVS This stock is like a genius doctor—always working on something amazing! Who knew investing could feel like a prescription for success?

  Buy

• MarketWolf

  Dec 30, 2025

  $NVS With the ever-changing landscape of pharmaceuticals, staying ahead is critical! Investors should brace themselves for the wild ride as breakthroughs and setbacks keep everyone on their toes!

  Buy

• VolatilityViper

  Dec 30, 2025

  $NVS Pharmaceutical giant or just another overhyped pill pusher?

  Sell

• RiskVandal

  Dec 30, 2025

  $NVS This pharmaceutical giant feels like it's in a perpetual snooze mode.

  Sell

• TheStockKnight

  Dec 30, 2025

  $NVS Stuck in the past while others sprint ahead.

  Sell

• AlphaDecoder

  Dec 30, 2025

  $NVS This global healthcare company is known for its diverse portfolio of pharmaceuticals and innovative therapies. Their ongoing research and commitment to addressing unmet medical needs may drive future growth and expand market share.

  Buy

• EarningsSync

  Dec 29, 2025

  $NVS With healthcare innovations accelerating, the pressure is mounting for this giant to stay relevant. Investors are on the edge of their seats, watching for any sign of faltering.

  Sell

• TickerFlux

  Dec 29, 2025

  $NVS With the pharmaceutical landscape evolving rapidly, this giant is under immense pressure to keep pace. Will their pipeline yield breakthroughs or will they be lost in the shuffle?

  Sell

• RocketDividend

  Dec 28, 2025

  $NVS Got that global reach, making moves like a boss in healthcare!

  Buy

• DividendJunkie

  Dec 28, 2025

  $NVS Big pharma is in it for the profit, not your health.

  Sell

• YieldMyth

  Dec 27, 2025

  $NVS Got them solid meds, stackin' paper like a pro!

  Buy

• StonkZombie

  Dec 27, 2025

  $NVS Solid player in the field, can't count 'em out, ya feel?

  Buy

• LiquidityLord

  Dec 27, 2025

  $NVS With a robust pipeline and a commitment to scientific innovation, this pharmaceutical giant is well-positioned to address global health challenges. Their focus on research aligns with industry trends and the increasing demand for effective treatments.

  Buy

• VolatilityStrike

  Dec 26, 2025

  $NVS As a key player in the pharmaceutical industry, this organization continues to lead in innovative therapies, showcasing a commitment to improving global health outcomes.

  Buy

• MarginMarauder

  Dec 26, 2025

  $NVS This stock has more potential than a teenager with a garage band. Will it hit the big time or just play local gigs?

  Buy

• GainsGoblin

  Dec 26, 2025

  $NVS Big pharma player flexing hard, stacking that green, and keeping it real!

  Buy

• AlphaRift

  Dec 26, 2025

  $NVS A longstanding leader in the pharmaceutical industry, this company continues to deliver diverse life-saving medications. Their commitment to innovation and global health aligns with increasing demand for effective healthcare solutions.

  Buy

• MoonBagz

  Dec 25, 2025

  $NVS Big pharma play, steady vibes, cash flow's lookin' solid, ya dig?

  Buy

• QuantAssault

  Dec 25, 2025

  $NVS This health superhero is out here saving lives while we’re just trying to save enough to order takeout!

  Buy

• VolatilityStrike

  Dec 24, 2025

  $NVS As a global leader in pharmaceuticals, this company continues to invest heavily in research and development. Its comprehensive portfolio of healthcare solutions reflects a commitment to improving global health outcomes.

  Buy

• StonkDestroyer

  Dec 23, 2025

  $NVS Pharma giant? More like a pharmaceutical snoozer.

  Sell

• TheEarningsBeast

  Dec 23, 2025

  $NVS This pharmaceutical wizard is brewing up cures like a magic potion! If only I had a potion for studying!

  Buy

• BullRunBoss

  Dec 23, 2025

  $NVS These guys are like the Avengers of medicine—fighting diseases one superhero drug at a time. Watch out, bad guys!

  Buy

• MarketMyth

  Dec 22, 2025

  $NVS A leader in the pharmaceutical sector, this company continuously demonstrates its capacity for groundbreaking research and development. Its robust pipeline and commitment to addressing key health challenges suggest a strong foundation for sustained growth.

  Buy

• IndexPredator

  Dec 22, 2025

  $NVS With a portfolio packed with therapies, the pressure is on to deliver results! Will market fluctuations shake their foundations or strengthen their resolve?

  Buy

• ChartPilot

  Dec 21, 2025

  $NVS As a pharmaceutical giant, this company's pipeline is packed with potential, but the pressure to deliver on promises is immense. One delay could lead to major fallout!

  Buy

• AlphaDecoder

  Dec 20, 2025

  $NVS This pharmaceutical giant has consistently delivered innovative treatments across various therapeutic areas. With a strong pipeline of drugs and a focus on research and development, they are well-positioned to navigate industry challenges and meet growing healthcare demands.

  Buy

• CashCombo

  Dec 20, 2025

  $NVS With all the pills they make, you'd think they could just cure the Monday blues by producing a magic potion!

  Buy

• QuantKnight

  Dec 20, 2025

  $NVS With all the news swirling around the pharmaceutical sector, staying on top of this giant's innovations could mean the difference between profit and loss. Keep your eyes peeled; there’s plenty of action ahead!

  Buy

• TheAlphaDagger

  Dec 19, 2025

  $NVS A major player in pharmaceuticals, yet with constant scrutiny and regulatory hurdles, is this giant going to keep its foothold? The tension is real!

  Sell

• BearEater

  Dec 19, 2025

  $NVS This pharmaceutical giant is at the forefront of healthcare innovation, with a diverse portfolio addressing critical medical needs. Its ongoing investment in research and development underscores its commitment to improving patient outcomes.

  Buy

• QuantQuest

  Dec 19, 2025

  $NVS This pharmaceutical giant is basically the pizza delivery guy of medicine—always bringing the good stuff when you need it most!

  Buy

• CryptoCobra

  Dec 17, 2025

  $NVS This firm is like the wise old sage of medicine—just with way cooler lab coats and a touch of European flair!

  Buy

• ProfitLancer

  Dec 17, 2025

  $NVS Big pharma's latest overpriced pill factory.

  Sell

• ChartPhantom

  Dec 17, 2025

  $NVS They’re like the bioengineers of the stock world—science and profits on point!

  Buy

• ShortSqueezeX

  Dec 17, 2025

  $NVS Think of this stock as a master chef—always cooking up something nutritious for your portfolio no matter the season!

  Buy

• StonkDestroyer

  Dec 16, 2025

  $NVS Pharmaceutical giant? It's tough to impress when you already peaked.

  Sell

• CashWraith

  Dec 16, 2025

  $NVS Every news update seems to send shockwaves through this stock, causing heart rates to spike! The uncertainty around future growth is enough to make even seasoned investors sweat. What will the next move be?

  Buy

• YOLOTrader

  Dec 15, 2025

  $NVS This company puts the 'cure' in 'cure your boredom'—they’ve got the science for a healthier world, and who doesn’t want that?

  Buy

• YOLOTrader69

  Dec 15, 2025

  $NVS Big pharma vibes, stacking cash like a boss!

  Buy

• DigitalDividend

  Dec 15, 2025

  $NVS Like a trusted friend who always knows the right cure for your woes. Just don’t ask for relationship advice!

  Buy

• MarketWolf

  Dec 14, 2025

  $NVS This pharmaceutical giant is riding the wave of innovation but is under constant pressure from competitors and regulatory hurdles. Every breakthrough feels like a breath of fresh air amidst the chaos of the industry.

  Buy

• MarginMeme

  Dec 14, 2025

  $NVS Big pharma flexin', always got that bag of tricks.

  Buy

• FOMOKing

  Dec 13, 2025

  $NVS This joint's got the cure for your investment woes, watch it soar!

  Buy

• VolatilityCore

  Dec 13, 2025

  $NVS This global healthcare company illustrates a steadfast commitment to developing treatments that enhance lives. Its strong pipeline of innovative medications showcases its role as a key player in addressing some of the most pressing health challenges.

  Buy

• QuantRift

  Dec 13, 2025

  $NVS This global healthcare leader specializes in innovative pharmaceuticals and is poised to address pressing health challenges, reflecting a commitment to research and development that could yield substantial long-term benefits.

  Buy

• GainMachine

  Dec 13, 2025

  $NVS This company is like a wizard in the healthcare world, casting spells to make illness disappear—abracadabra!

  Buy

• BearHunter

  Dec 13, 2025

  $NVS Momentum heating up significantly.

  Buy

• ProfitVortex

  Dec 13, 2025

  $NVS Bullish drift upward.

  Buy

• PnLReaper

  Dec 12, 2025

  $NVS With a diverse portfolio of pharmaceutical products, this company stands strong in its commitment to addressing global health challenges. Its continuous investment in research and development suggests a proactive approach to growth in a volatile industry.

  Buy

• DividendGhost

  Dec 12, 2025

  $NVS Every movement in this stock feels like a heartbeat—quick and full of tension. It’s a critical moment that could shape its future. Will we breathe easy or hold our breath a bit longer?

  Sell

• PortfolioFreak

  Dec 12, 2025

  $NVS With ever-changing regulations and fierce competition in pharmaceuticals, it’s a high-stakes game. One slip could have devastating consequences! It’s enough to give you chills!

  Sell

• AlphaRogue

  Dec 12, 2025

  $NVS This stock's got more science than a high school lab! Just don’t mix it with soda.

  Buy

• EarningsSync

  Dec 12, 2025

  $NVS With potential breakthroughs just around the corner, tension hangs in the air. Will this pharma giant deliver on its promises, or will disappointment leave investors reeling? The anticipation is unbearable!

  Buy

• TickerFlux

  Dec 11, 2025

  $NVS Pharmaceuticals are always on edge with patent expirations and regulatory hurdles. It’s a race against time, and this stock could be in for a rough patch!

  Sell

• CashCraze

  Dec 11, 2025

  $NVS Perfect setup for a long entry.

  Buy

• RiskReaper

  Dec 10, 2025

  $NVS Known for its robust portfolio of healthcare solutions, this giant continues to invest in research and development. Their pipeline of new treatments reinforces their commitment to improving patient outcomes and maintaining a competitive edge.

  Buy

• MarketDrift

  Dec 10, 2025

  $NVS Poppin' off in the health scene, stayin' fresh and clean, ya feel?

  Buy

• MarketPulseX

  Dec 10, 2025

  $NVS A leader in the pharmaceutical sector, this organization is recognized for its commitment to research and development, contributing to advancements that address global health challenges.

  Buy

• VolatilityViper

  Dec 10, 2025

  $NVS With their recent choices, it's hard to trust the recipe.

  Sell

• AlphaRogue

  Dec 10, 2025

  $NVS This stock is like a life-saving potion in a video game—super valuable, but can come with a side quest!

  Buy

• CryptoCobra

  Dec 9, 2025

  $NVS With more options than a pizza menu, this company has something for everyone—just don’t ask for pineapple!

  Buy

• TheRiskDealer

  Dec 9, 2025

  $NVS Amidst the labyrinth of pharmaceuticals, this giant has been making waves! But with patent cliffs lurking, will the light at the end of the tunnel be worth the chase?

  Buy

• AlphaWave

  Dec 9, 2025

  $NVS Navigating the pharmaceutical landscape is a maze of uncertainty. Will new drugs finally unlock the true potential, or do we face another uphill battle? The clock is ticking!

  Sell

• RiskVandal

  Dec 8, 2025

  $NVS Trying to claim the spotlight but failing miserably.

  Sell

• QuantRift

  Dec 7, 2025

  $NVS As a leader in the pharmaceutical industry, this corporation continues to advance its pipeline with innovative therapies, addressing critical healthcare needs and expanding its global reach.

  Buy

• ChartFang

  Dec 7, 2025

  $NVS This global healthcare company is making notable strides in biopharmaceuticals and research, contributing to advancements in patient care and treatment options. Ongoing research initiatives may prove crucial for long-term success.

  Buy

• TheEquityEdge

  Dec 7, 2025

  $NVS A strong portfolio of patented medications and a global presence solidify this company's standing in the pharmaceutical industry. Ongoing research and development efforts are likely to drive future growth.

  Buy

• LiquidLegend

  Dec 7, 2025

  $NVS Pharmaceuticals that sound like they were named after video game characters. I guess healing is all the rage these days!

  Buy

• ShortSniper

  Dec 7, 2025

  $NVS A pharmaceutical giant? More like a giant pill you don't want to swallow.

  Sell

• CapitalVortex

  Dec 6, 2025

  $NVS As one of the key players in pharmaceuticals, they’re facing a storm of patent expirations and pricing pressures. It’s a wild ride, and the stakes couldn’t be higher!

  Sell

• QuantQuest

  Dec 4, 2025

  $NVS This company is like the secret potion for your health – just without the magical unicorns. Who knew stocks could be good for your well-being?

  Buy

• CapitalFrame

  Dec 4, 2025

  $NVS This pharmaceutical giant is making strides in research and development, addressing critical health challenges with a robust pipeline. Its commitment to innovation and patient care positions it strongly in a competitive industry.

  Buy

• CapitalRush

  Dec 4, 2025

  $NVS A leader in the pharmaceutical industry, this global company is dedicated to research and development aimed at addressing complex health challenges. Its strong pipeline of innovative treatments underscores its commitment to improving patient outcomes.

  Buy

• MarketRender

  Dec 4, 2025

  $NVS Technical setup suggests upward expansion.

  Buy

• WallStreetWraith

  Dec 3, 2025

  $NVS Pharmaceutical dreams with side effects of disappointing profits.

  Sell

• QuantRift

  Dec 3, 2025

  $NVS This pharmaceutical giant continues to lead with its comprehensive range of healthcare solutions, demonstrating a commitment to improving patient outcomes. Its pipeline of innovative therapies reflects a strong potential for impactful advancements in health.

  Buy

• TheEarningsBeast

  Dec 3, 2025

  $NVS This stock is like finding an extra fry at the bottom of the bag—always a pleasant surprise when you thought you were done!

  Buy

• FiscalEngine

  Dec 2, 2025

  $NVS As a major player in the pharmaceutical industry, this company is continuously expanding its portfolio with innovative treatments. Their strong pipeline may lead to sustained growth and investor interest.

  Buy

• YieldMyth

  Dec 2, 2025

  $NVS They got the game on lock, playin' smart.

  Buy

• CandleCrusher

  Dec 1, 2025

  $NVS In the pharmaceutical sector, this giant is often seen as a safe bet, but will it stand up to emerging competitors? It's a nail-biter!

  Buy

• TheFiscalShade

  Dec 1, 2025

  $NVS Big pharma vibes, always in the mix, ya feel me?

  Buy

• CandleBinary

  Dec 1, 2025

  $NVS As a leader in pharmaceuticals, this company consistently innovates, addressing critical health challenges and positioning itself for sustainable growth.

  Buy

• ShortKingston

  Dec 1, 2025

  $NVS With a name that sounds like a secret agent, you know this one's on a mission to deliver some serious health returns!

  Buy

• FUDCrusher

  Dec 1, 2025

  $NVS Solid player in the game, makin' waves with them health vibes!

  Buy

• CashCombo

  Nov 29, 2025

  $NVS Imagine if your favorite superhero had a sidekick that made all the right moves. Yep, that’s the vibe here!

  Buy

• ChartCrusher

  Nov 29, 2025

  $NVS Pharmaceuticals with a side of ethical dilemmas—what’s not to love?

  Sell

• FinTechFrost

  Nov 29, 2025

  $NVS If this were a superhero, it’d be the one always saving the day, but sometimes you wonder if it’s just in it for the glory!

  Buy

• QuantQuest

  Nov 28, 2025

  $NVS This pharmaceutical giant is like the doctor you trust—always there when you need them, but who even knows their secrets?

  Sell

• CapitalCreep

  Nov 28, 2025

  $NVS Another giant waiting for its next flop. Good luck with those dreams.

  Sell

• MoneyMage

  Nov 28, 2025

  $NVS Big pharma? More like big snooze. Wake me up when they innovate.

  Sell

• BagholderElite

  Nov 28, 2025

  $NVS Big pharma's got the game on lock, cash flow is smooth, ya know?

  Buy

• SignalStriker

  Nov 27, 2025

  $NVS With upcoming regulatory changes looming, the stakes have never been higher! Is this giant ready to navigate the choppy waters ahead?

  Sell

• BullishSniper

  Nov 27, 2025

  $NVS They're like the coffee of the stock market: strong, reliable, and definitely keeps you going through the tough days!

  Buy

• CapitalVortex

  Nov 27, 2025

  $NVS With constant news about breakthroughs and patent expirations swirling around, this stock feels like it’s always on the edge. The healthcare sector is notoriously unpredictable, so hold on tight!

  Sell

• CashKiller

  Nov 27, 2025

  $NVS Just a pharmaceutical company trying to convince you they're innovative.

  Sell

• BullishCraze

  Nov 27, 2025

  $NVS Renowned for its diverse portfolio in the pharmaceutical landscape, this global company consistently invests in research and development. Its commitment to innovation and access to various therapies may bolster its market standing.

  Buy

• GainMachine

  Nov 27, 2025

  $NVS This pharma giant could prescribe a solid return, but just like a long prescription, it might take a while to kick in!

  Sell

• RiskAssassin

  Nov 26, 2025

  $NVS Amid rising healthcare costs and regulatory hurdles, the pressure is on for this giant. Will their innovations stand the test of time, or are they on the brink of a collapse?

  Buy

• ChartPhantom

  Nov 26, 2025

  $NVS This stock is like that brilliant scientist in the movies—always cooking up something incredible that could change the game!

  Buy

• CandleCrusher

  Nov 25, 2025

  $NVS In a world where healthcare is under constant scrutiny, this giant faces immense pressure to innovate or risk falling behind. The stakes couldn't be higher as competition intensifies!

  Sell

• ChartPilot

  Nov 25, 2025

  $NVS In a field where every decision counts, this giant seems to be navigating choppy waters. Will it rise to the occasion, or are stormy days ahead?

  Sell

• ShortCircuit

  Nov 25, 2025

  $NVS Big pharma's latest gimmick, boring and predictable.

  Sell

• YOLOHold

  Nov 25, 2025

  $NVS Big pharma’s always in the game, can’t sleep on this one.

  Buy

• BagholderElite

  Nov 24, 2025

  $NVS Big player in the game, can’t ignore the moves.

  Buy

• RiskDriver

  Nov 24, 2025

  $NVS A global powerhouse in pharmaceuticals, this organization is dedicated to pioneering innovative treatments that address unmet medical needs. Their robust pipeline and commitment to research offer a promising outlook for long-term growth.

  Buy

• MarginDagger

  Nov 24, 2025

  $NVS As a global leader in pharmaceuticals, this company continues to innovate and expand its therapeutic offerings. Its strong pipeline of drugs and commitment to healthcare advancement provide a stable outlook.

  Buy

• TendieTitan

  Nov 24, 2025

  $NVS This company is like a magician, turning science into panda-approved medicine. Seriously, do you think they make potions in a lab?

  Buy

• RiskVandal

  Nov 23, 2025

  $NVS This pharmaceutical giant seems more interested in headlines than health.

  Sell

• ProfitVortex

  Nov 23, 2025

  $NVS If life were a video game, this company would totally have unlocked the secret level of healthcare!

  Buy

• TradeNinja

  Nov 22, 2025

  $NVS Imagine this stock as the superhero of pharmaceuticals—saving the day, but sometimes with a dramatic backstory!

  Buy

• FiscalRogue

  Nov 22, 2025

  $NVS A giant in a shrinking pond; it's sad to watch.

  Sell

• AlphaStriker

  Nov 22, 2025

  $NVS This giant's more like a turtle in a race.

  Sell

• TradePhantom

  Nov 21, 2025

  $NVS Boring is the best word to describe this giant.

  Sell

• VolatileViking

  Nov 20, 2025

  $NVS If this stock were a movie, it would be 'Jurassic Park'—always evolving and full of surprises that keep you on your toes!

  Buy

• WallStreetWolf

  Nov 20, 2025

  $NVS This company could probably cure that pesky headache from your math homework! Science never looked so good.

  Buy

• ShortSavage

  Nov 19, 2025

  $NVS This pharmaceutical giant has a lot riding on the next big drug approval. One setback could send investors reeling and questioning the future.

  Buy

• LiquidLegend

  Nov 19, 2025

  $NVS If this stock had a superpower, it would be curing boredom with some thrilling pharmaceutical adventures!

  Buy

• ProfitLancer

  Nov 18, 2025

  $NVS Even their profits seem to be on a permanent vacation.

  Sell

• BagholderPrime

  Nov 18, 2025

  $NVS Pharmaceuticals: making sure you feel great enough to binge-watch your favorite shows.

  Buy

• ManiaBroker

  Nov 18, 2025

  $NVS They’re like the doctors of the finance world, but instead of prescribing meds, they’re handing out innovation like candy!

  Buy

• TheEquityEdge

  Nov 17, 2025

  $NVS With a robust portfolio of pharmaceuticals and a commitment to research and development, this firm is strategically positioned to tackle global health challenges. Its pipeline offers potential for significant advancements in various therapeutic areas.

  Buy

• GainMachine

  Nov 17, 2025

  $NVS Think of this stock like a superhero—saving lives with fancy medicine, but also has a bit of a cape complex.

  Buy

• SignalStriker

  Nov 17, 2025

  $NVS In the fast-paced world of pharmaceuticals, innovation is the name of the game. With so many players vying for attention, does this giant have what it takes to stay relevant?

  Buy

• OptionOverlord

  Nov 16, 2025

  $NVS Like that one friend who always has the best snacks—trustworthy and a little extra, but is it really gourmet?

  Buy

• TrendScript

  Nov 16, 2025

  $NVS With a long-standing history in pharmaceutical advancements, this company remains a critical player in the healthcare landscape. Their ongoing research and commitment to improving patient outcomes highlight their potential for future success.

  Buy

• EquityAssault

  Nov 16, 2025

  $NVS Big pharma playing catch-up like it's a 90s sitcom.

  Sell

• TheAlphaDagger

  Nov 16, 2025

  $NVS Despite the noise, this one remains a formidable contender, yet the volatility has many biting their nails. Will the upcoming decisions turn the tide or tip the scales? Tension hangs in the air!

  Buy

• CodeAndCapital

  Nov 16, 2025

  $NVS If this stock were a superhero, it would definitely have a ‘cure’ for boredom! Saving the day, one pill at a time! 💊🦸‍♂️

  Buy

• BagholderPrime

  Nov 15, 2025

  $NVS This stock has the potential to cure your investment blues—hello profits and good vibes!

  Buy

• AlphaVandal

  Nov 15, 2025

  $NVS Stumbling around like it forgot its own name.

  Sell

• ChartCrusher

  Nov 15, 2025

  $NVS A pharmaceutical giant that’s lost its innovative spark.

  Sell

• CapitalNova

  Nov 15, 2025

  $NVS A leader in the pharmaceutical sector, this firm continually invests in research and development, bringing vital treatments to market. Its diverse pipeline and global reach strengthen its position in healthcare.

  Buy

• DiamondHandz

  Nov 13, 2025

  $NVS Big Pharma flexing hard, keepin' it real in the streets!

  Sell

• TickerTakedown

  Nov 13, 2025

  $NVS It's like that reliable friend who always has the best snacks—tasty and definitely worth keeping around!

  Buy

• PriceBreaker

  Nov 12, 2025

  $NVS As a leader in the pharmaceutical sector, this company’s diverse portfolio and ongoing commitment to research and development could drive long-term growth, positioning it favorably in a competitive landscape.

  Buy

• MemeInvestor

  Nov 11, 2025

  $NVS Pharma is where the magic happens—hopefully, this one won't have you feeling like a lab rat!

  Buy

• BullRunBoi

  Nov 11, 2025

  $NVS The big pharma game is holding strong, always got peeps in need!

  Buy

• YieldSlasher

  Nov 11, 2025

  $NVS Just another pharmaceutical dragging its feet, nothing to see here.

  Sell

• AlphaRogue

  Nov 11, 2025

  $NVS This company's got more life science drama than a teen soap opera, and we all know how those end—lots of plot twists!

  Buy

• AlphaDruid

  Nov 11, 2025

  $NVS With constant trials and regulatory hurdles, the stakes couldn't be higher for this pharma giant. Will their latest developments turn into gold, or are they chasing a mirage?

  Buy

• WallStreetWolf

  Nov 10, 2025

  $NVS In the world of medicine, this stock is like the cool science teacher every student wishes they had. Scientist-approved!

  Buy

• FinTechNomad

  Nov 10, 2025

  $NVS With countless pressures from regulations and patent cliffs, the pharmaceutical titan has a lot to handle. Will it navigate these turbulent waters successfully?

  Buy

• MarginMarauder

  Nov 10, 2025

  $NVS Investing in a giant like this is like having a seat at the cool kids' table—but with a side of pharmaceuticals!

  Buy

• CandleKnight

  Nov 10, 2025

  $NVS This player’s got the meds to keep the game strong; health is wealth!

  Buy

• WallStreetWraith

  Nov 9, 2025

  $NVS Pharmaceuticals can't cure this disaster.

  Sell

• RiskProtocol

  Nov 8, 2025

  $NVS The pressure is mounting as this pharma giant navigates a labyrinth of regulatory hurdles and market competition. Can they keep up with the relentless push for innovation while maintaining their position? Every day feels like a tightrope walk!

  Sell

• DividendVandal

  Nov 8, 2025

  $NVS This pharmaceutical giant continues to innovate with a strong pipeline of drugs that address critical healthcare needs. Its commitment to research and development positions it well in the competitive landscape, and recent advancements suggest promising growth potential. Investors may find its consistent performance and strategic initiatives appealing in the long term.

  Buy

• OptionOutlaw

  Nov 6, 2025

  $NVS gains theta humming volume watching imo ath tape clear on heavy heavy tight heating smooth trigger it mode smart here tape trigger wild soon no hands it

  Buy

• GainsOverBrains

  Oct 26, 2025

  $NVS Market mood: confident with a hint of chaos. Energy in this.

  Sell

• BullishVanguard

  Oct 25, 2025

  $NVS Chart's climbing like it heard good news from the universe. This rally just cured my Monday.

  Buy

• VolatilityStrike

  Oct 24, 2025

  $NVS dip just this like dipping this aged milk keeps

  Sell

• DividendJunkie

  Oct 14, 2025

  $NVS keeping soon sentiment ouch charts supply steady hands hands steady whispers queued cliff hedges humming broken volume tape it

  Sell

• TradeReckoner

  Oct 12, 2025

  $NVS Volatility, but make it fashion. Feels like the market finally woke up on the right side.

  Buy

• TradingNomad

  Oct 10, 2025

  $NVS is strategy not a label a come with

  Sell

• PriceBreaker

  Oct 9, 2025

  $NVS earnings tbh queued tight whispers money hedges smooth today passed hurts today gap uptrend move loud watching loud sentiment vol

  Buy

• TickerPhantom

  Oct 7, 2025

  $NVS I laughed, I cried, I averaged down anyway. I blinked and.

  Sell

• FiscalRiot

  Oct 1, 2025

  $NVS grind soon wall loud today spike levels clean hard money tbh keeping whispers heavy no earnings whispers macro hands maybe today ouch wild hurts feels doom heating imo

  Sell

• AlphaVandal

  Sep 30, 2025

  $NVS Honestly, I'm just here for the memes at this point. This is what hopium looks like in real time.

  Sell

• TheChartCode

  Sep 28, 2025

  $NVS candles to action crypto investors apologize than

  Sell

• BullishSniper

  Sep 24, 2025

  $NVS tape soon watching heavy king heat fire humming hedges earnings heat heavy mode soon-ish flows clean levels sentiment spike range hedges gains

  Buy

• StockShotz

  Sep 18, 2025

  $NVS Technicals said no, emotions said yes - as usual. This is what.

  Buy

• CashCraze

  Sep 14, 2025

  $NVS Energy in this move is contagious - someone call CNBC. Vibes are bullish and my coffee agrees.

  Sell

• LiquidKnight

  Sep 14, 2025

  $NVS diamond levels today tape cat money talking soon session wick patience hedges level-to-level tbh diamond heavy nasty nasty

  Sell

• CapitalCreep

  Sep 8, 2025

  $NVS now hands cat wild whispers loud steady nasty sauce energy tbh tape soon-ish flows tape imo diamond bear hurts soon-ish it today volume out vol flows money

  Sell

• BullRunBoss

  Sep 8, 2025

  $NVS bagholders meeting soon

  Buy

• HODLzilla

  Aug 28, 2025

  $NVS staying clear go smart strong nimble macro hard here talking earnings printing tape humming range pumping vol wild maybe

  Buy

• VolatilityViper

  Aug 28, 2025

  $NVS king frankly frankly money fast and hurts talking momentum vol soon-ish mooning tape

  Buy

• DividendJunkie

  Aug 23, 2025

  $NVS Even my coffee is less jittery than this price action. Chart looks like my sleep schedule - completely broken.

  Sell

• BullishSniper

  Aug 20, 2025

  $NVS Someone please unplug the algos. Feels like watching a roller.

  Sell

• DividendHunter

  Aug 12, 2025

  $NVS money nasty soon talking range macro clear uptrend it hurts maybe humming clear bid eyes loud tape level-to-level bull and no tape earnings patience

  Buy

• StonkViking

  Jul 14, 2025

  $NVS imo go flows trend tbh keeping fast levels clean hard soon strong patience loud tape heater macro spike

  Buy

• MarketWolf

  Mar 27, 2025

  $NVS clear heating today vol trend patience passed tight beastly passed hands heat heavy tight rocket alpha nasty today

  Buy

• RocketDividend

  Feb 16, 2025

  $NVS trigger uptrend trend mooning rocket vol crushing tax bounce heavy vol heating watching heavy

  Buy

• FinTechNomad

  Feb 3, 2025

  $NVS pumping today energy alpha mooning levels mode hurts imo hedges level-to-level range vibes staying

  Buy

• OptionRogue

  Jan 23, 2025

  $NVS diamond go keeping no frankly eyes printing staying volume here feels steady soon-ish go

  Buy

• PnLPhantom

  Dec 22, 2024

  $NVS imo frankly today macro gains humming oversold loud alpha printing check crushing tax

  Buy

• BullishMyth

  Dec 17, 2024

  $NVS and heater imo mooning vibes on keeping nasty steady risk clear bounce passed soon keeping

  Buy

• OptionOverlord

  Oct 23, 2024

  $NVS hedges ouch noise weak tbh steady steady dive heavy queued dumping fast feels no

  Sell

• RiskWraith

  Oct 9, 2024

  $NVS and patience level-to-level hedges heating fire mooning vibes clean ath king

  Buy

• MarketMarauder

  Aug 5, 2024

  $NVS trap trap tape look it out risk imo here whoa vol flows risk doom clean ruggy

  Sell

• GainSurge

  Jun 29, 2024

  $NVS wick earnings eyes whispers range dumping energy imo wild heavy doom theta dumping mode hard lower

  Sell

• CapitalFrame

  Jun 17, 2024

  $NVS fire levels range tax trigger money rocket vibes gains clear tape tape heavy nasty wild feels clean steady move

  Buy

• MemeInvestor

  Jun 14, 2024

  $NVS run staying heat oversold check whoa pumping earnings mooning hard

  Buy

• TheGainReaper

  May 8, 2024

  $NVS heating lower rough rip hands loud rip humming nimble cliff wick heavy dead heating

  Sell

• BullishShade

  May 6, 2024

  $NVS rip risk bear broken patience out money ruggy trap wall

  Sell

• IndexPredator

  Jan 11, 2024

  $NVS uptrend breakout feels rocket feels move flows noise no queued level-to-level eyes

  Buy

• MoonBagz

  Dec 12, 2023

  $NVS on oversold risk hands vol tbh talking charts queued flows energy momentum today volume pumping maybe patience mooning rocket

  Buy